Jan 12, 2026 10:14AM
Dec 15, 2025 05:40PM
Dec 15, 2025 05:39PM
Nov 6, 2025 04:05PM
Nov 3, 2025 09:04AM
Aug 13, 2025 04:05PM
Aug 1, 2025 08:31AM Allogene drops experimental drug from lymphoma trial after patient death
Aug 1, 2025 08:30AM
Jun 1, 2025 10:45AM
May 22, 2025 05:21PM
May 22, 2025 05:17PM
Apr 23, 2025 10:12AM
Apr 7, 2025 08:31AM
Apr 7, 2025 08:30AM Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma
Mar 13, 2025 04:02PM
Feb 25, 2025 04:11PM
Feb 25, 2025 04:10PM
Feb 13, 2025 04:30PM
Feb 13, 2025 04:30PM
Jan 28, 2025 08:31AM
Jan 28, 2025 08:30AM Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
Jan 2, 2025 04:00PM
Nov 18, 2024 08:37AM
Nov 18, 2024 08:30AM
Nov 7, 2024 04:02PM
Nov 7, 2024 10:00AM
Nov 7, 2024 10:00AM
Nov 5, 2024 09:10AM Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidne
Oct 30, 2024 08:14AM
Oct 29, 2024 08:30AM
Oct 29, 2024 08:30AM
Sep 26, 2024 08:33AM
Sep 26, 2024 08:30AM
Aug 7, 2024 04:02PM
Jul 1, 2024 08:30AM Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Tr
Jun 20, 2024 08:30AM
May 13, 2024 04:01PM
Apr 26, 2024 08:32AM
Apr 26, 2024 08:30AM
Apr 26, 2024 08:30AM
Mar 14, 2024 04:05PM
Mar 12, 2024 08:30AM Allogene Therapeutics (ALLO) and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement
Mar 12, 2024 08:30AM
Jan 4, 2024 04:16PM
Jan 4, 2024 04:15PM
Jan 4, 2024 04:08PM
Jan 4, 2024 04:05PM
Jan 4, 2024 04:05PM
Dec 11, 2023 04:14AM Allogene Therapeutics (ALLO) Presents Safety Data of ALLO-647
Dec 9, 2023 12:00PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All